Target-independent variable region mediated effects on antibody clearance can be FcRn independent.
The importance of the neonatal Fc receptor (FcRn) in extending the serum half-life of monoclonal antibodies (mAbs) is well demonstrated, and has led to the development of multiple engineering approaches designed to alter Fc interactions with FcRn. Recent reports have additionally highlighted the effect of nonspecific interactions on antibody pharmacokinetics (PK), suggesting an FcRn-independent mechanism for mAb clearance. In this report we examine a case study of 2 anti-interleukin-12/23 antibodies, ustekinumab and briakinumab, which share the same target and Fc, but differ in variable region sequences. Ustekinumab displayed near baseline signal in a wide range of early stage developability assays for undesirable protein/protein interactions, while briakinumab showed significant propensity for self- and cross-interactions. This phenotypic difference correlates with faster clearance rates for briakinumab in both human FcRn transgenic and FcRn knockout mice. These findings support a dominant contribution for FcRn-independent clearance for antibodies with high nonspecificity, and highlight a key role for early stage developability screening to eliminate clones with such high nonspecific disposition PK.
a Department of Biological Engineering , Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Cambridge , MA , USA.
Ryan L
RL
Kelly
b Protein Analytics , Adimab , Lebanon , NH , USA.
Yao
Y
Yu
b Protein Analytics , Adimab , Lebanon , NH , USA.
Tingwan
T
Sun
b Protein Analytics , Adimab , Lebanon , NH , USA.
Isabelle
I
Caffry
b Protein Analytics , Adimab , Lebanon , NH , USA.
Heather
H
Lynaugh
b Protein Analytics , Adimab , Lebanon , NH , USA.
Michael
M
Brown
c Computational Biology , Adimab , Palo Alto , CA , USA.
Tushar
T
Jain
d Department of Chemical Engineering, Koch Institute for Integrative Cancer Research , Massachusetts Institute of Technology , Cambridge , MA , USA.
Yingda
Y
Xu
a Department of Biological Engineering , Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Cambridge , MA , USA.|d Department of Chemical Engineering, Koch Institute for Integrative Cancer Research , Massachusetts Institute of Technology , Cambridge , MA , USA.
K Dane
KD
Wittrup
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized; D000915:Antibody Affinity / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000276:immunology; D051379:Mice; D011961:Receptors, Fc / Q000276:immunology*; D000069549:Ustekinumab / Q000276:immunology / Q000493:pharmacokinetics*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015395:Histocompatibility Antigens Class I; D007135:Immunoglobulin Variable Region; D011961:Receptors, Fc; C544528:briakinumab; D000069549:Ustekinumab; C100688:Fc receptor, neonatal
Clearance; PK; cross-interaction; developability; monoclonal antibody; neonatal Fc receptor (FcRn); nonspecificity; polyreactivity; self-interaction